Scholarlink

<p>Recent advances in anti-cancer therapy have indicated the significance of the tumour immune microenvironment in tumour progression and resistance to anti-cancer therapy. This study investigated primary colorectal cancer (CRC) tissues resected from 180 cases in a single institute in a region highly endemic for human T-cell leukaemia virus type 1 (HTLV-1) carriers. Among those 180 cases, 35 HTLV-1 carriers were identified. CRC patients who were HTLV-1 carriers were significantly older (mean age: 76.9 vs. 72.7&#xa0;years, <i>P</i> = 0.0341), with a lower incidence of lymph node metastases (pN0: 91% vs. 65%, <i>P</i> = 0.0085), and lower tumour stages (stage III or IV: 11% vs. 36%, <i>P</i> = 0.0117) compared to non-carriers. HTLV-1 carriers tended to show a lower incidence of relapse, although the difference was not significant (<i>P</i> = 0.2272). The density of forkhead box P3-positive regulatory T cells (Tregs) was significantly higher in HTLV-1 carriers (median density: 132 vs. 89 cells/mm<sup>2</sup>, <i>P</i> = 0.0051). In situ hybridisation showed cells positive for <i>HTLV-1 basic leucine zipper factor</i>, likely representing lymphocytes located in stroma around the cancer nest. Our findings indicate that lymph node metastasis was significantly suppressed in CRC patients infected with HTLV-1. Since HTLV-1 infection reportedly impairs the immunosuppressive functions of Tregs, anti-cancer immune responses are potentially enhanced in CRC patients who are HTLV-1 carriers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of HTLV-1 infection on clinicopathological characteristics and tumour immune microenvironment in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月20日

查看全文
  • Rin Yamada,
  • Kota Arima,
  • Hiromu Yano,
  • Yukio Fujiwara,
  • Kohei Yamashita,
  • Kosuke Kanemitsu,
  • Norihisa Hanada,
  • Jun-Ichirou Yasunaga,
  • Masaaki Iwatsuki,
  • Yoshiki Mikami,
  • Yoshihiro Komohara

摘要

Recent advances in anti-cancer therapy have indicated the significance of the tumour immune microenvironment in tumour progression and resistance to anti-cancer therapy. This study investigated primary colorectal cancer (CRC) tissues resected from 180 cases in a single institute in a region highly endemic for human T-cell leukaemia virus type 1 (HTLV-1) carriers. Among those 180 cases, 35 HTLV-1 carriers were identified. CRC patients who were HTLV-1 carriers were significantly older (mean age: 76.9 vs. 72.7 years, P = 0.0341), with a lower incidence of lymph node metastases (pN0: 91% vs. 65%, P = 0.0085), and lower tumour stages (stage III or IV: 11% vs. 36%, P = 0.0117) compared to non-carriers. HTLV-1 carriers tended to show a lower incidence of relapse, although the difference was not significant (P = 0.2272). The density of forkhead box P3-positive regulatory T cells (Tregs) was significantly higher in HTLV-1 carriers (median density: 132 vs. 89 cells/mm2, P = 0.0051). In situ hybridisation showed cells positive for HTLV-1 basic leucine zipper factor, likely representing lymphocytes located in stroma around the cancer nest. Our findings indicate that lymph node metastasis was significantly suppressed in CRC patients infected with HTLV-1. Since HTLV-1 infection reportedly impairs the immunosuppressive functions of Tregs, anti-cancer immune responses are potentially enhanced in CRC patients who are HTLV-1 carriers.